Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited EPS (Diluted) for the year ending March 31, 2024: USD -0.07

Mangalam Drugs & Organics Limited EPS (Diluted) is USD -0.07 for the year ending March 31, 2024, a -805.77% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Mangalam Drugs & Organics Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.01, a -94.05% change year over year.
Mangalam Drugs & Organics Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.16, a -32.22% change year over year.
Mangalam Drugs & Organics Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.24, a 249.05% change year over year.
Mangalam Drugs & Organics Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.07, a 194.76% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Petrochemicals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years